The initial public offering (IPO) market has become red hot in recent weeks as market volatility begins to wane from the coronavirus pandemic-induced financial crisis. Five healthcare related companies and one special purpose accusation company (SPAC) joined the public market last week, adding to healthcare's recent domination of the IPO market. The week ahead plans to add a little more variety, with a large grocery chain and two tech related companies mixed in with more investor-favorite biotechs and one SPAC.

Last week's market was led by the debut of Royalty Pharma (RPRX  ), who increased over 59% on its first day of trading. The global leader in the pharmaceutical royalty industry priced its upsized offering at the high-end at $28 each to raise over $2.17 billion. The stock finished its first week up 75%.

For the rest of last week, Forma Therapeutics Holdings (FMTX  ) also offered its upsized deal at a price per share above its estimated range at $20 to raise over $277 million in its debut. The phase one hematologic disease biotech ended its first week up 95%. Genetron Holdings (GTH  ) raised $256 million its its IPO, pricing its shares at $16 each. The Chinese provider of cancer diagnostics finished the week relatively flat. Repare Therapeutics (RPTX  ) priced its deal at the high-end of its range to raise $220 million from shares initially priced at $20 each. The oncology biotech ended the week up 54%. PROGENITY (PROG  ) offered its public trading deal at the midpoint of its range to raise $100 million from shares priced at $15 each. The prenatal and disease screening company finished down 13%. Finally, the third SPAC offered by Fidelity National Financial (FNF  ), Trebia Acquisition, raised $450 million with the focus on a final services or technology company.

For the week ahead, highly anticipated Albertsons Companies plans to raise $1.5 billion from offering 65.8 million shares priced between $18-$20. The company is the fourth largest grocer in the United States, operating under the names Albertsons, Safeway and Vons.

Agora plans to raise $298 million from offering 17.5 million shares in the range of $16-$18 each. The Chinese API development platform has a large offering of software to embed audio, video and messaging for developers.

Akouos plans to raise over $153 million fro 8.3 million shares offered in the range of $14-$16 each. The preclinical biotech is focused on developing therapies for ear disorders.

Fusion Pharmaceuticals also aims to raise over $153 million from 8.35 million offered shares in the range of $14-$16 each. The phase one biotech is focused on medicines for solid tumors.

Ebang International plans to raise $106 million from over 19 million shares offered between $4.50-$6.50 each. The Chinese tech company is a global leader in the cryptocurrency mining industry.

PolyPid plans to raise over $61 million from 3.12 million share priced between $15-$17 each. The Israeli phase three surgical infection biotech is making its third attempt at going public after halting its IPO twice due to unfavorable market conditions.

The SPAC Brilliant Acquisition will finish out the week, targeting to raise $40 million to focus on any Asia Pacific business.